The price and value of therapeutic synergy in liver cancer

[1]  A. Gasbarrini,et al.  Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study , 2023, The Lancet.

[2]  B. Vincenzi,et al.  Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials. , 2023, JHEP reports : innovation in hepatology.

[3]  D. Pinato,et al.  NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  M. Kudo,et al.  Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study. , 2022, European journal of cancer.

[5]  P. Galle,et al.  LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC) , 2022, Annals of Oncology.

[6]  G. Cabibbo,et al.  Hepatitis B Virus-Associated Hepatocellular Carcinoma , 2022, Viruses.

[7]  M. Kudo,et al.  Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. , 2022, Journal of Clinical Oncology.

[8]  M. Kudo,et al.  Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. , 2021, The Lancet. Oncology.

[9]  J. Bruix,et al.  BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. , 2021, Journal of hepatology.

[10]  C. Porta,et al.  Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. , 2021, The New England journal of medicine.

[11]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[12]  Hashem B. El-Serag,et al.  Epidemiology of Hepatocellular Carcinoma , 2020, Hepatology.

[13]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[14]  M. Zoli,et al.  Prognosis of untreated hepatocellular carcinoma , 2015, Hepatology.